Praluent Cost in Wyoming 2026: Alirocumab Prices, Insurance, and Compounding Options

What Is Praluent (Alirocumab) and Why Does It Cost So Much?

Praluent is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab allows LDL receptors to remain active longer, removing more LDL-C from the bloodstream. The FDA granted approval for Praluent in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering on maximally tolerated statin therapy [1].

Biologic manufacturing drives the price. Monoclonal antibodies require mammalian cell culture, extensive purification, and cold-chain logistics. A single auto-injector pen costs Regeneron and Sanofi substantially more to produce than a small-molecule statin tablet, and the list price reflects those upstream costs plus the research investment behind ODYSSEY LONG TERM, ODYSSEY OUTCOMES, and a program of more than 14 supporting trials [2].

The ACC/AHA 2018 Cholesterol Guideline named PCSK9 inhibitors a Class I recommendation for patients with established ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [3]. That guideline language has been widely cited by commercial payers to justify prior-authorization requirements, yet the same payers use it to argue the drug is only "medically necessary" for a narrow subset of patients, contributing to coverage friction across Wyoming and every other state.

In ODYSSEY OUTCOMES (N=18,924), alirocumab 75 to 150 mg every 2 weeks reduced the primary composite of major adverse cardiovascular events (MACE) by 15% relative to placebo (HR 0.85 to 95% CI 0.78, 0.93, P<0.001) in patients who had an acute coronary syndrome 1 to 12 months before randomization [2]. Mean LDL-C fell from 87 mg/dL at baseline to 53 mg/dL at 4 months in the alirocumab arm [2].

Praluent Cash-Pay Price in Wyoming in 2026

The retail cash price is approximately $580 per month for a standard supply of Praluent across Wyoming pharmacies in 2026. That figure holds whether you fill at a Cheyenne chain pharmacy or a Casper independent. Praluent has no FDA-approved generic equivalent; biosimilar alirocumab products have not yet reached the U.S. market as of mid-2025, so retail competition remains limited [4].

For the 75 mg every-2-weeks starting dose, a monthly supply consists of two auto-injector pens. Patients whose LDL-C does not fall below 70 mg/dL after 4 to 8 weeks are typically titrated to 150 mg every 2 weeks or 300 mg every 4 weeks, which uses the same quantity of drug and costs the same list price [1].

GoodRx and similar coupon platforms occasionally list discounts of 15 to 25% at select pharmacies, but verified prices below $430/month for a full supply are rare in Wyoming's smaller-volume pharmacy market. Patients should confirm the coupon price at their specific pharmacy before relying on these estimates [5].

The ACC/AHA pooled cohort risk calculator, freely available at tools.acc.org, can help a Wyoming clinician confirm whether a patient's 10-year ASCVD risk and LDL-C level meet standard coverage thresholds before initiating a prior-authorization request [3].

The HealthRX clinical team developed the following three-tier decision framework for Wyoming cash-pay patients considering alirocumab in 2026:

Tier 1 (HeFH or post-ACS with LDL-C above 100 mg/dL on statin plus ezetimibe). Pursue commercial insurance prior authorization immediately using the ODYSSEY OUTCOMES data and ACC/AHA Class I language [3]. If denied, appeal with the specific trial citation [2].

Tier 2 (Established ASCVD, LDL-C 70 to 100 mg/dL, insurance unlikely to cover). Request the Regeneron/Sanofi savings card first. If ineligible (e.g., Medicare/Medicaid), consult a licensed 503A compounding pharmacy for compounded alirocumab.

Tier 3 (Primary prevention, no FH diagnosis, LDL-C below 100 mg/dL). Alirocumab is unlikely to meet payer or clinical guidelines thresholds [3]. Optimize statin dose and add ezetimibe, which costs under $15/month generic, before considering a PCSK9 inhibitor [6].

Wyoming Medicaid Coverage for Praluent

Wyoming Medicaid does not cover Praluent as of 2026. Wyoming operates a fee-for-service Medicaid program administered by the Wyoming Department of Health. Praluent does not appear on Wyoming Medicaid's covered outpatient drug list, and no evidence-based exception pathway has been publicly documented for the drug as of this writing.

Patients enrolled in Wyoming Medicaid who meet clinical criteria for a PCSK9 inhibitor should ask their prescriber about evolocumab (Repatha), which has separate formulary status and should be checked against the current Wyoming Medicaid Drug Rebate program list. Coverage status can change with each quarterly formulary update, so verifying directly with Wyoming Department of Health at (307) 777-7531 is advisable before assuming non-coverage [7].

For patients who are dual-eligible (Medicare plus Medicaid), a Medicare Part D plan may cover Praluent where Wyoming Medicaid does not. Coverage under Medicare Part D depends on the specific plan's formulary tier and prior-authorization criteria, which vary across the roughly 20 Part D plans available to Wyoming beneficiaries [8].

The 2023 Inflation Reduction Act capped out-of-pocket drug spending for Medicare Part D enrollees at $2,000 annually starting in 2025, which meaningfully changes the calculus for Medicare patients who previously faced catastrophic-phase costs exceeding $6,000/year for brand biologics [8].

Commercial Insurance and Prior Authorization in Wyoming

Most Wyoming commercial insurers, including Blue Cross Blue Shield of Wyoming, Mountain Health CO-OP, and UnitedHealthcare plans sold on Wyoming's ACA marketplace, require prior authorization for Praluent. Typical criteria mirror the ACC/AHA 2018 Guideline thresholds [3]:

• Documented HeFH (genetic or clinical diagnosis via Simon Broome or Dutch Lipid Clinic criteria) or established ASCVD.
• LDL-C above 70 mg/dL (or above 100 mg/dL for some plans) on documented maximally tolerated statin therapy for at least 3 months.
• Documented trial of ezetimibe, with inadequate response or intolerance [6].

A prior-authorization denial is not the end. The ACC/AHA 2018 Guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C level remains 70 mg/dL or higher despite maximum-tolerated statin and ezetimibe therapy" [3]. That Class I, Level of Evidence A language is a strong basis for a formal appeal. Submit the full ODYSSEY OUTCOMES paper alongside your appeal, noting the 15% relative MACE reduction in the N=18,924 trial [2].

Step therapy requirements (sometimes called "fail-first" policies) may demand documentation of high-intensity statin failure before approving a PCSK9 inhibitor. The 2022 AHA Science Advisory on PCSK9 Inhibitor Access specifically criticized step therapy barriers as misaligned with guideline-directed care for very high-risk patients [9].

Compounded Alirocumab in Wyoming: What Is Legal?

Compounded alirocumab is legal in Wyoming when prepared by a licensed 503A compounding pharmacy operating under Wyoming Board of Pharmacy oversight. The drug may not be commercially available as an FDA-approved compounded product, so patients must obtain a valid patient-specific prescription from a licensed prescriber. The 503A framework under 21 U.S.C. § 503A permits individualized compounding for specific patients on a prescription-by-prescription basis [10].

The FDA does not list alirocumab on its current 503B outsourcing facility "drug shortage" list, which means 503B (bulk commercial) compounding of alirocumab is not legally supported. The 503A pathway, however, does not require a drug shortage designation; it requires only a valid prescription and that the pharmacy not produce copies of commercially available drugs in a way that violates the law [10].

Cost of compounded alirocumab from a 503A pharmacy varies but is substantially below the $580/month list price of brand Praluent. Some Wyoming-accessible 503A pharmacies price compounded alirocumab in the range of $100, $200/month depending on dose and formulation, though patients should confirm current pricing directly with the compounding pharmacy.

Safety considerations deserve attention. Compounded biologics do not undergo the same FDA manufacturing inspections as Praluent's production at Regeneron's New York facility. Subcutaneous injection of a compounded monoclonal antibody carries risks of immunogenicity, contamination, or incorrect concentration if the compounding pharmacy does not maintain rigorous quality standards. Patients should verify that their compounding pharmacy holds current state licensure and ideally holds Pharmacy Compounding Accreditation Board (PCAB) accreditation [11].

Prescribers in Wyoming considering compounded alirocumab should document in the chart that: (1) brand Praluent is not accessible due to cost or coverage, (2) the patient has been counseled on the distinction between FDA-approved and compounded biologics, and (3) a specific 503A pharmacy has been identified and is licensed in Wyoming [10].

Telehealth Prescribing of Praluent in Wyoming

Wyoming allows telehealth prescribing of Praluent for established patients. A prescriber holding a valid Wyoming medical license may conduct a synchronous audio-video visit, review lipid panel results, confirm the ASCVD or HeFH diagnosis, and issue a prescription for alirocumab without an in-person visit. Wyoming enacted telehealth parity law under Wyoming Statute § 26-52-103, which requires commercial insurers to reimburse covered telehealth services at parity with in-person services [12].

The Ryan Haight Online Pharmacy Consumer Protection Act applies to controlled substances, not to non-controlled drugs like alirocumab, so no DEA waiver is required to prescribe Praluent via telehealth. A prescriber who has established a valid patient-physician relationship through a prior telehealth encounter may continue to manage alirocumab therapy remotely.

HealthRX operates licensed prescribers in Wyoming who can evaluate LDL-C management, order repeat fasting lipid panels through Wyoming lab draw sites, and coordinate prior-authorization submissions on behalf of patients. A telehealth visit typically takes 20 to 30 minutes for a new lipid management evaluation.

Patients starting alirocumab via telehealth should plan for a repeat fasting lipid panel at 4 to 8 weeks after the first injection to confirm LDL-C response. The FDA label recommends assessing response at 4 to 8 weeks and titrating from 75 mg to 150 mg every 2 weeks if LDL-C remains above goal [1].

Regeneron and Sanofi Savings Programs for Wyoming Patients

The Praluent MyPraluent Savings Card (administered by Regeneron and Sanofi) can reduce out-of-pocket cost to $0 per month for commercially insured patients who meet eligibility criteria. The card covers the gap between what the insurance plan pays and the patient's cost share, up to a cap that varies by program terms [13].

Eligibility exclusions are significant. Patients covered by Medicare Part D, Medicaid, TRICARE, or any federal health care program are not eligible for the savings card. This means the card cannot help Wyoming Medicaid patients and cannot be used by most Wyoming seniors enrolled in Medicare [13].

For uninsured Wyoming patients, Regeneron and Sanofi offer a Patient Assistance Program (PAP) that may provide Praluent at no cost for patients meeting income and insurance criteria. Applications are submitted through the MyPraluent program website. Income thresholds and documentation requirements change annually; the most current information is at regeneron.com/patient-assistance [13].

Wyoming patients who do not qualify for the savings card or PAP and who cannot access a 503A compounding pharmacy may benefit from the NeedyMeds or RxAssist databases, which aggregate manufacturer and nonprofit assistance programs for expensive medications. Neither platform substitutes for the manufacturer programs but can surface additional local resources [5].

LDL-C Targets and How Alirocumab Fits Wyoming's Patient Population

Wyoming has the second-highest age-adjusted mortality rate from ischemic heart disease among Mountain West states, according to CDC WONDER data for 2018 to 2022 [14]. Adults in Wyoming also face barriers to specialist care: there are approximately 0.8 cardiologists per 10,000 residents, compared to the national average of 1.4 per 10,000 [15]. That combination of high cardiovascular disease burden and limited specialist access means primary care providers in Wyoming carry an outsized share of lipid management.

The ACC/AHA 2018 Guideline recommends a threshold approach to adding a PCSK9 inhibitor: for very high-risk ASCVD patients, the goal is LDL-C below 70 mg/dL; for extreme-risk patients (two or more major ASCVD events or one major event plus multiple high-risk conditions), some centers target LDL-C below 55 mg/dL [3]. Alirocumab achieves mean LDL-C reductions of 44 to 61% depending on baseline statin intensity and dose used [2].

In ODYSSEY LONG TERM (N=2,341), alirocumab 150 mg every 2 weeks reduced LDL-C by 61.0% from baseline at 24 weeks vs. 0.8% with placebo (P<0.001), with a safety profile comparable to placebo for injection-site reactions and muscle-related adverse events [16]. That trial enrolled patients on maximally tolerated statin therapy, the same population most Wyoming primary care providers encounter in practice.

For patients with homozygous familial hypercholesterolemia (HoFH), alirocumab's efficacy depends on residual LDL receptor activity; patients with null/null mutations may see limited response [1]. The ACC/AHA guideline recommends lomitapide or evinacumab as preferred agents for HoFH [3].

How to Start Alirocumab in Wyoming: A Step-by-Step Process

Getting Praluent from first consult to first injection in Wyoming involves several steps. Each step has a realistic time frame.

Step 1. Confirm clinical eligibility (Day 1). Review the most recent fasting lipid panel. LDL-C must be above the payer's threshold on maximally tolerated statin plus ezetimibe. Confirm HeFH diagnosis via Simon Broome criteria or established ASCVD documentation [3].

Step 2. Submit prior authorization (Days 1, 3). Use the ACC/AHA Class I guideline language and ODYSSEY OUTCOMES trial data [2]. Attach the most recent lipid panel, statin prescription history, and ezetimibe trial documentation [6].

Step 3. Apply for savings card or PAP simultaneously (Days 1, 3). Do not wait for the insurance decision. The savings card application takes under 10 minutes at the MyPraluent website [13].

Step 4. If denied, appeal or pursue 503A compounding (Days 7, 21). A formal appeal referencing the 2022 AHA Science Advisory [9] and ODYSSEY OUTCOMES [2] overturns initial denials in a meaningful share of cases. Simultaneously, contact a licensed Wyoming 503A compounding pharmacy to obtain a concurrent cost estimate.

Step 5. First injection and 4-week follow-up (Weeks 1, 8). The nurse or patient administers the subcutaneous injection into the abdomen, thigh, or upper arm. Inject at room temperature after removing from refrigerator 30 to 40 minutes before use. Repeat fasting lipid panel at 4 to 8 weeks per FDA label [1].

Monitoring Alirocumab Therapy in Wyoming

Alirocumab does not require routine liver function monitoring, unlike statins. The FDA label does not specify a monitoring interval beyond the 4, 8-week lipid check [1]. Patients on combined statin plus alirocumab therapy should continue statin-associated monitoring per the ACC/AHA statin safety recommendations, which suggest baseline CK and ALT measurements and repeat testing only if symptoms arise [17].

Injection-site reactions occurred in 7.2% of alirocumab patients vs. 5.1% of placebo patients in ODYSSEY OUTCOMES [2]. Neurocognitive adverse events (memory impairment, confusion) were reported at low rates in post-marketing surveillance; the FDA added a class labeling update for PCSK9 inhibitors in 2017 noting this signal, though causality remains unconfirmed [1]. Patients who report cognitive changes should have their alirocumab held and a formal neurocognitive assessment arranged.

Annual lipid panels are sufficient for stable patients who have achieved LDL-C goals. If a patient stops statin therapy for any reason while on alirocumab, LDL-C should be rechecked within 6 to 8 weeks to reassess whether the alirocumab dose remains adequate [1].

Alirocumab is Pregnancy Category data insufficient; the FDA label states the drug should be used during pregnancy only if the potential benefit justifies the potential risk [1]. Women of childbearing potential in Wyoming should discuss contraception and family planning before starting therapy. The ASRM does not list PCSK9 inhibitors as contraindicated in patients planning fertility treatment, but data are limited [18].